WO2021261926A1 - 치매치료를 위한 장기지속형 주사제 - Google Patents
치매치료를 위한 장기지속형 주사제 Download PDFInfo
- Publication number
- WO2021261926A1 WO2021261926A1 PCT/KR2021/007916 KR2021007916W WO2021261926A1 WO 2021261926 A1 WO2021261926 A1 WO 2021261926A1 KR 2021007916 W KR2021007916 W KR 2021007916W WO 2021261926 A1 WO2021261926 A1 WO 2021261926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rivastigmine
- microspheres
- pamoate salt
- present
- biocompatible polymer
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 13
- 238000002347 injection Methods 0.000 title description 4
- 239000007924 injection Substances 0.000 title description 4
- 206010012289 Dementia Diseases 0.000 title description 2
- 239000004005 microsphere Substances 0.000 claims abstract description 110
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims abstract description 100
- 229960004136 rivastigmine Drugs 0.000 claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 44
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims description 23
- 208000015114 central nervous system disease Diseases 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000935 solvent evaporation Methods 0.000 claims description 8
- 238000000638 solvent extraction Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- -1 polyhydroxyvalate Substances 0.000 claims description 4
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 2
- 239000002745 poly(ortho ester) Substances 0.000 claims description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 239000004632 polycaprolactone Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 9
- 238000013268 sustained release Methods 0.000 abstract description 7
- 239000012730 sustained-release form Substances 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000012071 phase Substances 0.000 description 31
- 239000000839 emulsion Substances 0.000 description 16
- 230000000052 comparative effect Effects 0.000 description 15
- 239000003960 organic solvent Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000005538 encapsulation Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229920002451 polyvinyl alcohol Polymers 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 238000005915 ammonolysis reaction Methods 0.000 description 5
- 238000013270 controlled release Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- GWHQHAUAXRMMOT-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;[3-[1-(dimethylamino)ethyl]phenyl] n-ethyl-n-methylcarbamate Chemical compound OC(=O)C(O)C(O)C(O)=O.CCN(C)C(=O)OC1=CC=CC(C(C)N(C)C)=C1 GWHQHAUAXRMMOT-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000010419 fine particle Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 239000003021 water soluble solvent Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960004323 rivastigmine tartrate Drugs 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- KMJTTWREVXZPTK-UHFFFAOYSA-M n-ethyl-n-methylcarbamate Chemical compound CCN(C)C([O-])=O KMJTTWREVXZPTK-UHFFFAOYSA-M 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Definitions
- the present invention relates to a long-acting injection for the treatment of dementia, and more particularly, to microspheres comprising rivastigmine pamoate salt, made of a biocompatible polymer, and a method for preparing the same.
- the drug-containing or drug-containing particles are either coated by one or more release delaying layers or dispersed within microspheres, such as a polymer matrix.
- the coating layer or matrix comprises a relatively insoluble material, and the release of the drug can be controlled by the resistance or permeability of the coating layer or matrix to the diffusion of the drug.
- rivastigmine is a cholinesterase inhibitor used for the treatment of mild to severe Alzheimer's disease and Parkinson's disease, and is sold under trade names such as Exelon. Rivastigmine improves symptoms in Alzheimer's patients by preventing the breakdown of acetylcholine in the central nervous system. The increased availability of acetylcholine allows for improved neurotransmission and thus improvements in memory and cognitive function.
- Rivastigmine is currently administered in the form of oral capsules and transdermal patches.
- oral capsules they are administered in doses of 1.5 mg, 3 mg, 4.5 mg, and 6 mg, and since the oral half-life of the drug is very short, about 1.5 hours, it is prescribed in the form of administration twice a day.
- transdermal patches products are released in 4.6mg, 9.5mg, and 13.3mg doses, and they are prescribed in the form of one patch per day.
- the transdermal dosage form has the advantage of being able to release a relatively controlled drug, extending the dosing interval and improving patient compliance, but still has a limitation in that it must be applied daily.
- Korean Patent Application No. 10-2012-7003314 discloses a sustained-release drug having both short-acting and long-acting properties.
- No. 661441 a time-controlled sustained-release formulation containing rivastigmine is presented.
- the time-controlled sustained-release method using a semi-permeable membrane causes the time-controlled drug to be released at once after a certain period of time. Side effects are still a concern.
- the rapid initial release of rivastigmine is controlled to provide continuous drug release and absorption, while the encapsulation rate of the drug is improved to extend the dosing cycle, thereby increasing the patient's medication compliance. Demand is increasing.
- microspheres comprising rivastigmine pamoate salt and made of a biocompatible polymer.
- Another object of the present invention is to prepare a dispersed phase using (a) rivastigmine pamoate salt and a biocompatible polymer using one or more solvents; (b) adding the prepared dispersed phase to the continuous phase and stirring to form microspheres; And (c) to provide a method for producing the microsphere comprising the step of removing the solvent.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of central nervous system diseases comprising microspheres.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of central nervous system diseases consisting essentially of microspheres.
- Another object of the present invention is to provide the use of microspheres for preparing a preparation for the treatment of central nervous system diseases.
- Another object of the present invention is to provide a method for treating a central nervous system disease comprising administering to an individual in need thereof an effective amount of a composition comprising microspheres.
- the present invention provides microspheres comprising 10 to 80% by weight of rivastigmine pamoate salt, and made of a biocompatible polymer.
- the present invention comprises the steps of (a) preparing a dispersed phase of rivastigmine pamoate salt and a biocompatible polymer using one or more solvents; (b) adding the prepared dispersed phase to the continuous phase and stirring to form microspheres; And (c) provides a method for producing the microsphere comprising the step of removing the solvent.
- the present invention provides a pharmaceutical composition for preventing or treating central nervous system disease comprising the microspheres.
- the present invention provides a pharmaceutical composition for preventing or treating central nervous system diseases essentially consisting of the microspheres.
- the present invention provides the use of the microspheres for preparing a preparation for the treatment of central nervous system diseases.
- the present invention provides a method for treating a central nervous system disease comprising administering to an individual in need thereof an effective amount of a composition comprising the microspheres.
- the present invention provides microspheres comprising rivastigmine pamoate salt in an amount of 10 to 80% by weight and made of a biocompatible polymer.
- the rivastigmine has a chemical name [3-[(1S)-1-(dimethylamino)ethyl]phenyl]N-ethyl-N-methylcarbamate ([3-[(1S)- As a compound of 1-(dimethylamino)ethyl]phenyl]N-ethyl-N-methylcarbamate), rivastigmine or a pharmaceutically acceptable salt thereof is known as a drug useful for the prevention and treatment of Alzheimer's disease and Parkinson's disease.
- the rivastigmine pamoate salt exhibits pharmacological activity of the same nature as previously reported for free rivastigmine and other acid addition salts.
- the rivastigmine pamoate salt contained in the microspheres may exhibit an improving effect of neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
- the content of the rivastigmine pamoate salt contained in the microspheres may be 10 to 80% by weight. If the content of rivastigmine pamoate salt contained in the microspheres exceeds 80% by weight, the initial release amount of rivastigmine in the body environment is too high, which may cause a problem in that the blood concentration of the drug rises rapidly. When the content of the rivastigmine pamoate salt is less than 10% by weight, there may be a problem in that the administration becomes difficult because the proportion of the biocompatible polymer is relatively high and the dosage becomes excessive.
- the content of the rivastigmine pamoate salt contained in the microspheres may be 15 to 75% by weight, more preferably 20 to 70% by weight, most preferably 25 to 65% by weight. have.
- microspheres provided by the present invention mean that the rivastigmine pamoate salt is encapsulated in microspheres prepared using a biocompatible polymer, and in the present specification, they are simply rivastigmine-containing microspheres, rivastigmine microspheres or microspheres, etc. is referred to as As long as the rivastigmine pamoate salt is encapsulated in microspheres prepared using a biocompatible polymer, all of them fall within the scope of the present invention without limitation on the type of biocompatible polymer used.
- the biocompatible polymer may be selected based on intrinsic viscosity.
- a suitable intrinsic viscosity is 0.1 to 1.9 dL/g, preferably 0.1 to 1.4 dL/g, more preferably 0.1 to 0.9 dL/g.
- the decomposition of the polymer is so fast that it may be difficult to continuously release rivastigmine until a desired time, and if the intrinsic viscosity exceeds 0.9 dL/g, the polymer Due to the slow decomposition of rivastigmine, the amount of rivastigmine released may not be effective.
- the biocompatible polymer may contain 20 to 90% by weight, preferably 25 to 80% by weight, even more preferably 30 to 80% by weight, most preferably 35 to 75% by weight based on the total weight of the microspheres. have.
- the biocompatible polymer when included in an amount of less than 20% by weight, the distribution of rivastigmine pamoate salt is relatively increased, and there may be a problem in that it is not possible to maintain the drug effect for the initial excessive release or the desired period, and if it exceeds 90% by weight, If included, the amount to be administered to the patient may become too large, making administration difficult or administration impossible.
- the ratio of rivastigmine to be encapsulated in microspheres made of a biocompatible polymer according to the type of its salt shows a significant difference.
- the encapsulation rate in the biocompatible polymer microspheres was less than 60%, and other salts did not show an encapsulation rate to the extent that it can be used industrially.
- rivastigmine pamoate salt exhibited a high encapsulation rate of 80% or more.
- the microspheres may provide encapsulated rivastigmine in a controlled or extended release form.
- the controlled or extended release form may be understood to have the same meaning as “sustained release”, “controlled release” or “delayed release”.
- the microspheres may be characterized in that the release of encapsulated rivastigmine in an in vivo or in vitro environment lasts for 24 hours or more.
- the rivastigmine contained in the microspheres is released to 20% or less, more preferably 15% or less within 24 hours after entering the use environment, and the remainder is continuously released after 24 hours can be done with
- the microspheres may be characterized in that the release of encapsulated rivastigmine in an in vivo or in vitro environment lasts for 1 day to 12 weeks.
- the rivastigmine contained in the microspheres is released to 20% or less, more preferably 15% or less within 24 hours after entering the use environment, and the remainder is continuously released for a period of 2 to 12 weeks. It can be characterized as being
- the microspheres may be characterized in that the release of encapsulated rivastigmine in an in vivo or in vitro environment lasts for 1 to 4 weeks.
- the rivastigmine contained in the microspheres is released to 20% or less, more preferably 20% or less within 24 hours after entering the use environment, and the remainder is continuously released for a period of 1 to 4 weeks. It can be characterized as being
- the microspheres containing rivastigmine pamoate salt are solvent evaporation or extraction method through an emulsion, more preferably, O/W containing a biocompatible polymer, rivastigmine pamoate salt and a dispersion solvent It may be prepared by an O/W type solvent evaporation method in which an (oil-in-water) type emulsion is prepared and it is agglomerated into fine particles.
- Microspheres comprising rivastigmine pamoate salt can be prepared by various methods for preparing microspheres known in the art (eg, O/W type, O/O type or W/O/W type solvent evaporation method or solvent extraction method, spraying
- O/W type O/O type or W/O/W type solvent evaporation method or solvent extraction method
- spraying When prepared according to the solvent evaporation method or solvent extraction method through O/W type emulsion among microsphere production method by drying, microsphere production method by phase separation, etc.), the encapsulation rate of rivastigmine pamoate salt in microspheres can be significantly improved. have.
- an O/W type emulsion containing a biocompatible polymer, rivastigmine pamoate salt, and a dispersion solvent is prepared do.
- a conventional method known in the art may be used for the preparation of the O/W type emulsion, and more specifically, for the preparation of the O/W type emulsion, a dispersed phase containing a biocompatible polymer and rivastigmine pamoate salt is used. It can be prepared by adding to a dispersion solvent.
- These rivastigmine pamoate salt-containing polymer particles are prepared by agglomeration of an emulsion into fine particles by solvent evaporation or solvent extraction, or by agglomeration by ammonolysis or hydrolysis.
- ammonolysis process ammonia is added, and in the case of the hydrolysis process, the ammonolysis or hydrolysis reaction occurs due to the addition of an acid or base, so that the water-insoluble organic solvent is converted into a water-soluble solvent.
- the solvent extraction method includes a conventional solvent extraction method used for preparing rivastigmine pamoate salt-containing polymer microspheres, such as effectively extracting the organic solvent in the emulsion droplets using a large amount of solubilizing solvent.
- Aggregation by the ammonolysis process is, for example, as in the method described in Korean Patent No. 918092, by adding ammonia to an O/W type emulsion containing a water-insoluble organic solvent to induce ammonolysis, and converting the water-insoluble organic solvent into a water-soluble solvent.
- a method of transforming the particles to agglomerate is shown.
- the high molecular compound of step (a) is polyglycolic acid, polylactic acid, polyglycolide, polylactide, polylactic-co-glycolic acid, polylactide-co-glycolide (PLGA), polyphosphazine, polyi Minocarbonate, polyphosphoester, polyanhydride, polyorthoester, copolymer of lactic acid and caprolactone, polycaprolactone, polyhydroxyvalate, polyhydroxybutyrate, polyamino acid, copolymer of lactic acid and amino acid and mixtures thereof, and most preferably polylactide-co-glycolide (PLGA).
- PLGA polylactide-co-glycolide
- the present invention also comprises the steps of (a) preparing a dispersed phase of rivastigmine pamoate salt and a biocompatible polymer using one or more solvents; (b) adding the prepared dispersed phase to the continuous phase and stirring to form microspheres; And (c) provides a method for producing the microsphere comprising the step of removing the solvent.
- Step (a) is a step of preparing a dispersed phase comprising a rivastigmine pamoate salt and a biocompatible polymer.
- the amount of rivastigmine pamoate salt is 10 to 400 parts by weight, preferably 15 to 300 parts by weight, more preferably 25 to 250 parts by weight, most preferably based on 100 parts by weight of the biocompatible polymer. may be dispersed or dissolved in 30 to 200 parts by weight.
- the type of solvent used for preparing the organic phase is not particularly limited, but dichloromethane, chloroform, and the like may be used.
- Step (b) is a step of solidifying the microspheres by dispersing the dispersed phase prepared in step (a) in an external continuous phase to prepare an emulsion solution (O/W).
- a hydrophilic polymer may be included as a surfactant, and the type thereof is not particularly limited, and the dispersed phase containing the rivastigmine pamoate salt and the biocompatible polymer is stable in the external continuous phase. Anything that can help form a dispersed phase can be used.
- the hydrophilic polymer is preferably methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyvinyl alcohol, polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene sorbitan fatty acid ester and polyoxyethylene It may be selected from the group consisting of castor oil derivatives and mixtures thereof, and most preferably polyvinyl alcohol.
- the external continuous phase in step (b) may be 0.1 to 3% (w/w) of a hydrophilic polymer aqueous solution, in this case, the molecular weight of the hydrophilic polymer may be 10,000 to 30,000, and the degree of hydrolysis may be 80 to 90% .
- step (b) the hydrophilic polymer is added to the dispersed phase comprising the rivastigmine pamoate salt and biocompatible polymer prepared in step (a) in a drop-by-drop method or in a method using an in-line mixer.
- An emulsion solution (O/W) is prepared by addition to the included external continuous phase and vigorous stirring.
- the rivastigmine pamoate salt is encapsulated into biocompatible polymer microspheres.
- step (c) the solvent is removed in step (c), and the desired microspheres can be obtained after normal filtration and washing. That is, if necessary, the step of washing the obtained microspheres using an organic solvent such as ethanol to improve the initial release inhibitory effect may be included.
- the weight of the rivastigmine pamoate salt encapsulated in the microspheres obtained according to the above preparation method is 55% or more of the weight of the rivastigmine pamoate salt dissolved in step (a).
- the encapsulation rate of rivastigmine pamoate in the microspheres may be 55% or more.
- the weight of the rivastigmine pamoate salt encapsulated in the microspheres obtained according to the above preparation method is 60% or more of the weight of the rivastigmine pamoate salt dissolved in step (a).
- the encapsulation rate of rivastigmine pamoate in the microspheres may be 60% or more.
- the central nervous system disease may preferably be Alzheimer's disease or Parkinson's disease.
- the pharmaceutical composition according to the present invention may contain the microspheres alone or may be formulated in a suitable form together with a pharmaceutically acceptable carrier, and may further contain excipients or diluents.
- the carrier includes all kinds of solvents, dispersion media, oil-in-water or water-in-oil emulsions, aqueous compositions, liposomes, microbeads and microsomes.
- the pharmaceutically acceptable carrier may further include, for example, a carrier for parenteral administration.
- Carriers for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycol, and the like, and may further contain stabilizers and preservatives. Suitable stabilizers include antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol.
- the pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, etc. in addition to the above components.
- Other pharmaceutically acceptable carriers and agents may refer to those known in the art.
- compositions of the present invention may be administered by methods generally known in the art.
- the injection of the present invention can be administered parenterally.
- Parenteral administration methods include, but are not limited to, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, vaginal, intrapulmonary, suppository, topical , to a patient (eg, a person in need thereof) or other animal by sublingual or rectal administration.
- Formulations for parenteral administration may be formulated in the form of injections, creams, lotions, external ointments, oils, moisturizers, gels, aerosols and nasal inhalants by methods known in the art. These formulations are described in formulary commonly known in all pharmaceutical chemistry.
- the total effective amount of the composition of the present invention may be administered to a patient as a single dose, or may be administered by a fractionated treatment protocol in which multiple doses are administered for a long period of time.
- the pharmaceutical composition of the present invention may vary the content of the active ingredient according to the severity of the disease.
- the preferred total dose of the pharmaceutical composition of the present invention may be about 0.01 ⁇ g to 10,000 mg, most preferably 0.1 ⁇ g to 500 mg per kg of the patient's body weight per day.
- the dosage of the pharmaceutical composition is determined by considering various factors such as the formulation method, administration route and number of treatments, as well as the patient's age, weight, health status, sex, severity of disease, diet and excretion rate, etc., the effective dosage for the patient is determined.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.
- the present invention provides the use of the microspheres for preparing a preparation for the treatment of central nervous system diseases.
- the present invention provides a method for treating a central nervous system disease comprising administering to an individual in need thereof an effective amount of a composition comprising the microspheres.
- the 'effective amount' of the present invention refers to an amount that, when administered to an individual, has the effect of improving, treating, preventing, detecting, diagnosing, or inhibiting or reducing a disease of the central nervous system, and the 'individual' is an animal, preferably may be mammals, particularly animals, including humans, and may be cells, tissues, organs, etc. derived from animals.
- the subject may be a patient in need of the effect.
- the 'treatment' of the present invention refers to ameliorating central nervous system disease or symptoms of the disease, which may include curing, substantially preventing, or ameliorating the condition of the disease, the disease including, but not limited to, alleviating, curing or preventing one or most of the symptoms resulting from
- the term 'comprising' is used synonymously with 'including' or 'characterized by', and in the composition or method according to the present invention, specifically Additional components or method steps that have not been excluded are not excluded.
- the term 'consisting of' means excluding additional elements, steps, or ingredients that are not separately described.
- the term 'essentially consisting of' means that, in the scope of the composition or method, it may include substances or steps that do not substantially affect its basic properties in addition to the substances or steps described.
- 1A to 1C are results of observation of the microspheres prepared in Comparative Examples 1, 2, and 2 of the present invention with a scanning electron microscope (SEM).
- Figure 2 shows the experimental results of evaluating the initial release rate of rivastigmine rivastigmine tartrate salt (Comparative Example 1) and rivastigmine pamoate salt (Example 2) encapsulated microspheres.
- rivastigmine tartrate 2.00 g was dissolved in 100 ml of ultrapure water, and 3.02 g of disodium pamoate was completely dissolved in 100 ml of ultrapure water. Rivastigmine tartrate solution was placed in a beaker and disodium pamoate solution was slowly added thereto under stirring at 300 rpm to obtain rivastigmine pamoate salt, and lyophilized.
- polyvinyl alcohol molecular weight: 9,000-10,000
- aqueous solution 0.5% polyvinyl alcohol (molecular weight: 9,000-10,000) aqueous solution was used.
- 1,000 ml of the continuous phase was placed in a production tank at 25° C., and the prepared dispersed phase was injected using an in-line mixer (Silverson, UK) to prepare microspheres. Thereafter, the temperature was raised to 25° C. and the organic solvent was removed for 5 hours. After washing the prepared microspheres with water for injection several times, residual polyvinyl alcohol was removed and the microspheres were freeze-dried.
- Example 2 Preparation of rivastigmine pamoate microspheres containing rivastigmine pamoate salt
- polyvinyl alcohol molecular weight: 13,000-23,000
- aqueous solution 0.5% polyvinyl alcohol (molecular weight: 13,000-23,000) aqueous solution was used. 1000 ml of the continuous phase was put into a production tank at 25° C., and the prepared dispersed phase was injected using an in-line mixer (Silverson, UK) to prepare microspheres. Thereafter, the temperature was raised to 25° C. and the organic solvent was removed for 5 hours. After washing the prepared microspheres with water for injection several times, residual polyvinyl alcohol was removed and the microspheres were freeze-dried.
- polyvinyl alcohol molecular weight: 13,000-23,000
- FIGS. 1A to 1C The results of measuring the morphology of the microspheres are shown in FIGS. 1A to 1C .
- Figure 1a is Comparative Example 1
- Figure 1b is Comparative Example 2
- Figure 1c is a morphological observation photograph of the microspheres in Example 2.
- Example 2 did not have pores and were spherical in a uniform shape compared to Comparative Examples 1 and 2.
- microspheres containing rivastigmine pamoate salt according to the present invention exhibit stable drug release for a long period of time, and thus can maintain an effective concentration of rivastigmine in the blood for a certain period of time, thereby prolonging the administration cycle of the drug and improving the patient's It has high industrial applicability as it can improve medication compliance and reduce side effects caused by rapid initial release of the drug.
Abstract
Description
봉입률(%) | |
비교예 1 | 59.12 |
비교예 2 | 10.78 |
실시예 2 | 82.00 |
Claims (11)
- 리바스티그민 파모에이트 염(rivastigmine pamoate salt)을 10 내지 80중량%로 포함하며, 생체적합성 고분자로 이루어진 미립구.
- 제1항에 있어서, 상기 미립구는 리바스티그민 방출이 24시간 이상 지속되는 것을 특징으로 하는 미립구.
- 제1항에 있어서, 상기 미립구에 포함된 리바스티그민은 사용 환경에 진입한 후 24시간 이내에 20중량% 이하로 방출이 되는 것을 특징으로 하는 미립구.
- 제1항에 있어서, 상기 생체적합성 고분자는 폴리락트산, 폴리락타이드, 폴리락틱-코-글리콜산, 폴리락타이드-코-글리콜라이드(PLGA), 폴리포스파진, 폴리이미노카보네이트, 폴리포스포에스테르, 폴리안하이드라이드, 폴리오르쏘에스테르, 락트산과 카프로락톤의 공중합체, 폴리카프로락톤, 폴리하이드록시발레이트, 폴리하이드록시부티레이트, 폴리아미노산, 락트산과 아미노산의 공중합체 및 이들의 혼합물로 이루어진 군에서 선택되는 것을 특징으로 하는 미립구.
- 제1항에 있어서, 상기 미립구는 생체적합성 고분자, 리바스티그민 파모에이트 염 및 분산용매를 포함하는 O/W (oil-in-water)형 용매증발법 또는 용매추출법에 따라 제조된 것을 특징으로 하는 미립구.
- (a) 리바스티그민 파모에이트 염 및 생체적합성 고분자를 1종 이상의 용매를 이용하여 분산상을 제조하는 단계;(b) 상기 제조된 분산상을 연속상에 넣고 교반하여 미립구를 형성시키는 단계; 및(c) 상기 용매를 제거하는 단계를 포함하는, 제1항 내지 제5항 중 어느 한 항에 따른 미립구의 제조방법.
- 제6항에 있어서, 상기 (a) 단계에서 리바스티그민 파모에이트 염은 상기 생체적합성 고분자 100중량부에 대하여 10 내지 400중량부로 분산되거나 용해되는 것을 특징으로 하는 제조방법.
- 제6항에 있어서, 상기 제조방법에 따라 수득된 미립구에 봉입된 리바스티그민 파모에이트 염의 중량은 상기 (a) 단계에서 용해시킨 리바스티그민 파모에이트 염의 중량 대비 50% 이상인 것을 특징으로 하는 제조방법.
- 제1항 내지 제5항 중 어느 한 항에 따른 미립구를 포함하는 중추신경계 질환 예방 또는 치료용 약학적 조성물.
- 중추신경계 질환 치료용 제제를 제조하기 위한 제1항 내지 제5항 중 어느 한 항에 따른 미립구의 용도.
- 제1항 내지 제5항 중 어느 한 항에 따른 미립구를 포함하는 조성물의 유효량을 이를 필요로 하는 개체에 투여하는 것을 포함하는 중추신경계 질환 치료 방법.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0076727 | 2020-06-23 | ||
KR1020200076727A KR20210158232A (ko) | 2020-06-23 | 2020-06-23 | 치매치료를 위한 장기지속형 주사제 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021261926A1 true WO2021261926A1 (ko) | 2021-12-30 |
Family
ID=79178642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/007916 WO2021261926A1 (ko) | 2020-06-23 | 2021-06-23 | 치매치료를 위한 장기지속형 주사제 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR20210158232A (ko) |
WO (1) | WO2021261926A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120072750A (ko) * | 2010-12-24 | 2012-07-04 | 주식회사 삼양바이오팜 | 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법 |
KR20140120496A (ko) * | 2013-04-03 | 2014-10-14 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
US20160310411A1 (en) * | 2011-11-29 | 2016-10-27 | Zi-Qiang Gu | Rivastigmine pamoate, memantine pamoate, methods of preparation and uses thereof |
KR20190064509A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
KR20210007924A (ko) * | 2019-07-12 | 2021-01-20 | 주식회사 지투지바이오 | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 |
-
2020
- 2020-06-23 KR KR1020200076727A patent/KR20210158232A/ko not_active Application Discontinuation
-
2021
- 2021-06-23 WO PCT/KR2021/007916 patent/WO2021261926A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120072750A (ko) * | 2010-12-24 | 2012-07-04 | 주식회사 삼양바이오팜 | 수난용성 약물 함유 서방성 마이크로입자 및 그 제조방법 |
US20160310411A1 (en) * | 2011-11-29 | 2016-10-27 | Zi-Qiang Gu | Rivastigmine pamoate, memantine pamoate, methods of preparation and uses thereof |
KR20140120496A (ko) * | 2013-04-03 | 2014-10-14 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
KR20190064509A (ko) * | 2017-11-30 | 2019-06-10 | 주식회사 지투지바이오 | 안전성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법 |
KR20210007924A (ko) * | 2019-07-12 | 2021-01-20 | 주식회사 지투지바이오 | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 |
Also Published As
Publication number | Publication date |
---|---|
KR20210158232A (ko) | 2021-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014163400A1 (ko) | 도네페질을 포함하는 비경구투여용 약제학적 조성물 | |
WO2019078583A1 (ko) | 약물을 포함하는 지속 방출형 마이크로 입자 및 이의 제조 방법 | |
WO2010024615A2 (ko) | 용매교류증발법에 의한 서방출성 미립구의 제조방법 | |
WO2021010719A1 (ko) | 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법 | |
WO2020197190A1 (en) | Method for preparing biocompatible polymer-based apixaban-loaded microspheres | |
WO2018221884A1 (ko) | 방출제어가 용이한 서방성 약물 미립자의 제조방법 | |
WO2022010317A1 (ko) | 도네페질 함유 서방출성 plga 미립구의 제조방법 | |
WO2021091246A1 (ko) | 초기 방출 제어가 가능한 서방출성 미립구 및 이의 제조 방법 | |
WO2010053306A2 (ko) | 메칠페니데이트의 방출 제어용 약제학적 조성물 | |
WO2016021835A1 (ko) | 약물 함유 서방성 미립자의 제조 방법 | |
WO2021261926A1 (ko) | 치매치료를 위한 장기지속형 주사제 | |
WO2021091333A1 (ko) | 지속 방출을 위한 마이크로스피어 및 이의 제조 방법 | |
EP3188720A1 (en) | Tadalafil oral dispersible film and preparing method thereof | |
WO2020242234A1 (ko) | 캐스파제 저해제 프로드럭을 함유하는 주사용 조성물 및 이의 제조 방법 | |
WO2020180093A2 (ko) | 오셀타미비르 함유 의약 조성물 | |
WO2023101348A1 (ko) | 류프로라이드를 포함하는 마이크로 입자 및 이의 제조 방법 | |
WO2020130585A1 (ko) | 데슬로렐린을 함유하는 서방형 주사제 및 그 제조방법 | |
WO2023038202A1 (ko) | 생분해성 고분자를 이용한 서방형 미립구 및 이의 제조방법 | |
WO2019221488A1 (en) | Pharmaceutical formulation comprising apixaban and method for preparing the same | |
WO2021242021A1 (ko) | 글루카곤 유사 펩타이드 1 작용제 함유 제어방출 미립구 및 이의 제조방법 | |
WO2023085503A1 (ko) | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
WO2019132229A1 (ko) | 도네페질을 함유하는 치매 치료용 경피흡수제제 | |
WO2024063424A1 (ko) | 바리시티닙을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물 | |
WO2014163215A1 (ko) | 쓴 맛이 차폐된 약제학적 조성물 | |
WO2021167364A1 (en) | Pharmaceutical composition comprising esomeprazole and sodium bicarbonate having excellent release properties |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21828434 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828434 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21828434 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/06/2023) |